NCT04589234View on ClinicalTrials.gov

Saltikva for Metastatic Pancreatic Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

Salmonella-IL2

Phase 2 study to determine the anti-tumor effectiveness of Salmonella-IL2 (Saltikva) with standard of care chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane) for metastatic pancreatic cancer

DRUG

FOLFIRINOX Alone (Historical Controls)

We will use historical data from the literature to compare FOLFIRINOX alone against the FOLFIRINOX with Salmonella-IL2 group

DRUG

Gemcitabine/Abraxane Alone (Historical Controls)

We will use historical data from the literature to compare Gemcitabine/Abraxane alone against the Gemcitabine/Abraxane with Salmonella-IL2 group

Trial Locations (1)

H3T 1E2

Segal Cancer Centre/ Mortimer B. Davis-Jewish General Hosptial, Montreal

All Listed Sponsors
lead

Salspera LLC

INDUSTRY